California researchers screened some 850 miRNAs to uncover one that inhibits growth in cancer cells with KRAS mutations, which are linked to poor survival.
Under the deal, Horizon's X-Man human discovery cell lines will be used to test the effects of common mutations in cancer patients on the efficacy of Mirna's miRNA mimics.
The release of the data comes on the heels of a publication in Cell showing that therapeutic miRNA delivery could suppress tumorigenesis in a mouse model of liver cancer, which Mirna's CEO said bolsters the company's strategy.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.